SHC — Sotera Health Company

Sotera Health Company (SHC) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Revenue: Increased by 10% to $280 million, or 6.5% on a constant currency basis compared to Q1 2025.
• Net Income: GAAP net income was $27 million, or $0.9 per diluted share.
• Adjusted EBITDA: Grew 10.5% to $135 million, with a margin expansion of over 20 basis points.
• Adjusted EPS: Increased to $0.18 per share, up approximately 29% year-over-year.
• Interest Expense: Improved by $6 million to $35 million due to term loan repricing and debt paydown.
• Operating Cash Flow: Generated $29 million, including a $34 million payment for a legal settlement.
• Capital Expenditures: Totaled $46 million, focused on facility expansions and upgrades.
• Net Leverage Ratio: Finished the quarter at 3.2x, nearing the target range of 2x to 3x.

2. Strategic Updates and Business Highlights:

• Segment Performance:
  • Sterigenics: Revenue grew 9.7% to $186 million (6.1% constant currency), impacted by localized weather but showing strong pricing and volume growth.
  • Nordion: Revenue surged 29% to $42 million (25.8% constant currency), driven by increased volume and favorable pricing.
  • Nelson Labs: Revenue declined slightly by 0.7% to $52 million (3.8% constant currency), with margins under pressure due to lower volume/mix.
• Governance Changes: Alton Shader appointed as new CEO effective May 2026, with Michael Petras transitioning to Executive Chair.
• Legal Developments: Positive outcomes in Georgia with the dismissal of eight bellwether personal injury cases related to Sterigenics.

3. Forward Guidance and Outlook:

• 2026 Revenue Guidance: Expected to range from $1.233 billion to $1.251 billion, reflecting 5% to 6.5% constant currency growth.
• Adjusted EBITDA Guidance: Anticipated to improve to $632 million to $641 million, representing 5.5% to 7% constant currency growth.
• Segment Expectations:
  • Sterigenics: Mid- to high-single-digit constant currency growth.
  • Nordion: Low- to mid-single-digit growth.
  • Nelson Labs: Low single-digit growth with margin improvement expected throughout the year.

4. Bad News, Challenges, or Points of Concern:

• Nelson Labs: Experienced a decline in revenue and margins, attributed to lower volume/mix and headwinds from Expert Advisory Services.
• Weather Impact: Sterigenics faced localized weather challenges that affected volumes in Q1.
• Regulatory Uncertainty: Ongoing discussions regarding ethylene oxide emissions regulations could impact future operations and capital expenditures.

5. Notable Q&A Insights:

• Sterigenics Growth: Management indicated that Q1 was expected to be the lightest quarter, with strong growth anticipated in Q2 despite weather-related impacts.
• Capacity Utilization: Current utilization is at targeted levels, with plans for new facilities to support future growth.
• Pricing Strategy: Pricing remains stable, with Sterigenics achieving a 4.5% increase in Q1, slightly above the long-term guidance of 3% to 4%.
• Expert Advisory Services Impact: The decline in Nelson Labs was partially due to a headwind from Expert Advisory Services, but routine testing volumes are expected to recover as sterilization volumes increase.

This summary encapsulates the key financial metrics, strategic initiatives, forward guidance, and notable challenges faced by Sotera Health Company in Q1 2026, providing a comprehensive overview for stakeholders.